CORGARETIC - 40 TABLETS

국가: 남아프리카

언어: 영어

출처: South African Health Products Regulatory Authority (SAHPRA)

제공처:

Bm_squib

환자 정보 전단

CORGARETIC - 80 TABLETS
CORGARETIC - 40 TABLETS
SCHEDULING STATUS:
S3
APPROVED PP ZIMBABWE ONLY
PROPRIETARY NAME
(and dosage form)
CORGARETIC - 80 
TABLETS
CORGARETIC - 40 
TABLETS
COMPOSITION
CORGARETIC-80 tablets contain 80 mg of 
nadolol
; 2,3 Cis-1,2,3,4- tetrahydro-5- [2-hydroxy-3- (tert-butyl-amino)
propoxy] -2,3- naphthalenediol in combination with 5 mg 
bendroflumethiazide
; 3-benzyl-3,4-dihydro-6-
(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide. 
CORGARETIC-40 tablets contain 40 mg of nadolol; 2,3 Cis-1,2,3,4- tetrahydro-5- [2-hydroxy-3- (tert-butyl-amino)
propoxy] -2,3- naphthalenediol in combination with 5 mg bendroflumethiazide; 3-benzyl-3,4-dihydro-6-
(trifluoromethyl)-2H-1,2,4-benzothia diazine-7-sulphonamide 1,1-dioxide.
PHARMACOLOGICAL CLASSIFICATION
Category A 7.1.3 Other Hypotensives
PHARMACOLOGICAL ACTION
CORGARETIC is an antihypertensive which combines nadolol, a non-selective beta-adrenergic receptor blocking agent,
and bendroflumethiazide, a diuretic/antihypertensive.
Nadolol and bendroflumethiazide produce an additive therapeutic effect in reducing elevated blood pressure.
INDICATIONS
Hypertension.
CONTRA-INDICATIONS
ALLERGY TO ANY OF THE COMPONENTS
Nadolol is contra-indicated for patients with bronchial asthma; chronic respiratory diseases; allergic rhinitis during the
pollen season; sinusbradycardia; cardiogenic shock and all degrees of heart block greater than first degree AV block and
bradycardia less than 50 per minute; right ventricular failure secondary to pulmonary hypertension; congestive heart
failure (see Warnings); patients receiving adrenergic-augmenting psychotropic drugs (including MAO inhibitors), and
during a two-week withdrawal period from such drugs, peripheral vascular diseases and Raynaud's phenomenon; heart
failure; renal failure and hepatic failure. 
WARNINGS
NADOLOL
Caut